Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_assertion type Assertion NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_head.
- NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_assertion description "[We found that EMT developed in a lung cancer patient who had an acquired resistance to erlotinib while there were no known resistant mechanisms such as T790M and MET amplification.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_provenance.
- NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_assertion evidence source_evidence_literature NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_provenance.
- NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_assertion SIO_000772 21168239 NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_provenance.
- NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_assertion wasDerivedFrom befree-2016 NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_provenance.
- NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_assertion wasGeneratedBy ECO_0000203 NP860048.RAMDfjx9qk_NiSG1R5V2H9ro25fjrkPPmeSgtPYD6sF4w130_provenance.